MétaCan
Menu
Back to cohort
Record W2587612082 · doi:10.1093/ecco-jcc/jjx002.823

P699 Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study

2017· article· en· W2587612082 on OpenAlexaffabout
John K. Marshall, Neeraj Narula, Gerald Lebovic, Brad Millson, Katia Charland, Mike Sung, Tania Gaetano, Kevin J. McHugh, Martin G. Latour, Marie-Claude Laliberté

Bibliographic record

VenueJournal of Crohn s and Colitis · 2017
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsSt. Michael's HospitalABB (Canada)University of TorontoMcMaster UniversityPopulation Health Research Institute
Fundersnot available
KeywordsMedicineAdalimumabInflammatory bowel diseaseInternal medicineUlcerative colitisCrohn's diseasePhysical therapyCohortPoisson regressionDiseasePopulation

Abstract

fetched live from OpenAlex

Background: Adalimumab (ADL) is an anti-TNF biologic therapy indicated for the treatment of inflammatory bowel diseases (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC). Patients receiving ADL in Canada are eligible to enroll in the AbbVie Care patient support program (PSP) which provides them with personalized services including ongoing care coach calls (CCC). In a previous study, IBD patients enrolled in Abbvie Care receiving CCC demonstrated significantly greater persistence and adherence to ADL than patients that did not receive CCC (no-CCC). The objective of this study is to compare the likelihood of achieving clinical remission in a cohort of IBD patients treated with ADL enrolled in the ADL PSP between those who received CCC versus those who did not receive CCC. Methods: A longitudinal analysis using de-identified aggregate-level data collected through the AbbVie Care PSP was performed. Patients were indexed on the date of their first injection of ADL between January 2010 and October 2015. The ADL PSP database included patient measurements of the Harvey-Bradshaw Index (HBI), a measure of disease severity. To be eligible, patients had to have a baseline HBI measurement 90 days before to 30 days after their index date and have had a follow up HBI measurement 6 to 18 months later. HBI remission (HBI≤4) at the time of the follow up HBI assessment was compared in patients having received CCC and patients without CCC (no CCC). Robust Poisson regression was used to estimate the adjusted relative risk (RR) of HBI remission. Analyses were adjusted for patient age group, sex, region, prior biologic use, days lapsed between HBI assessments, and baseline disease severity category. Results: A total of 1469 IBD patients met eligibility criteria and 916 (62%) of these had received CCC. Of the 1469 patients, 1046 (71%) were in HBI remission at the second assessment, 682 (74%) in the CCC group and 364 (66%) in the group not receiving CCC. In the multivariable regression analysis, there was a 12% increased likelihood of achieving HBI remission in the CCC group relative to the group without CCC (RR=1.12, 95% confidence interval: 1.04, 1.20; p-value =0.002). Conclusions: IBD patients receiving tailored services through the ADL PSP in the form of care coach calls have an increased likelihood of achieving HBI remission within 6 to 18 months. These results may help refine interventions aiming at improving clinical outcomes in IBD patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.008
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.002
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.340
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicInflammatory Bowel DiseaseFrench-language works237,207